I look forward to seeing studies investigating the hypothesis put forth by by this paper:
We hypothesize topical application of bevacizumab could inhibit corneal neovascularization and also scarring in HSK. We propose this drug as a novel adjunct to current anti-inflammatory strategies in HSK.